Rovi rises after EBITDA beats consensus

Laboratorios Farmaceuticos Rovi

24/07/2025 09:44

** Shares in Rovi ROVI.MC rise around 4% after the Spanish drugmaker reported better than expected earnings

** Sabadell says the results are in line with operational expectations, with Q2 EBITDA at 35 million euros versus 33 million euros seen in consensus

** Jefferies says H1 results were in line with consensus at sales level, and 4% above at the EBITDA level

** It also notes the low-molecular-weight heparin (LMWH) business was a strong growth contributor in H1

** "The ramp up of Okedi and decreases in Heparin raw material prices increased margins driving the beat versus consensus," Jefferies adds

** Up to the previous session's close, shares were down 13.6%​ year-to-date

 (Reporting by Marta Serafinko in Gdansk)

 ((Marta.Serafinko@thomsonreuters.com; +48 58 769 66 00;))